Orlistat associated subacute hepatic failure

被引：23

作者：

Montero, JL ^{[1
]}

Muntané, J

Fraga, E

Delgado, M

Costán, G

Serrano, M

Padillo, J

de la Mata, M

Miño, G

机构：

[1] Hosp Reina Sofia, Dept Gastroenterol, Cordoba, Spain

[2] Hosp Reina Sofia, Dept Surg, Cordoba, Spain

[3] HOsp Gen Especialidades, Dept Gastroenterol, Jaen, Spain

来源：

JOURNAL OF HEPATOLOGY | 2001年 / 34卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(00)00042-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：173 / 173

页数：1

共 4 条

[1] Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].

Davidson, MH ;

Hauptman, J ;

DiGirolamo, M ;

Foreyt, JP ;

Halsted, CH ;

Heber, D ;

Heimburger, DC ;

Lucas, CP ;

Robbins, DC ;

Chung, J ;

Heymsfield, SB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242

[2] Role of orlistat in the treatment of obese patients with type 2 diabetes - A 1-year randomized double-blind study [J].

Hollander, PA ;

Elbein, SC ;

Hirsch, IB ;

Kelley, D ;

McGill, J ;

Taylor, T ;

Weiss, SR ;

Crockett, SE ;

Kaplan, RA ;

Comstock, J ;

Lucas, CP ;

Lodewick, PA ;

Canovatchel, W ;

Chung, J ;

Hauptman, J .

DIABETES CARE, 1998, 21 (08) :1288-1294

[3] Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients [J].

Sjöström, L ;

Rissanen, A ;

Andersen, T ;

Boldrin, M ;

Golay, A ;

Koppeschaar, HPF ;

Krempf, M .

LANCET, 1998, 352 (9123) :167-172

[4] Classification, etiology, and considerations of outcome in acute liver failure [J].

Williams, R .

SEMINARS IN LIVER DISEASE, 1996, 16 (04) :343-348

← 1 →